Long-term survival of patients with stage II and III gastric cancer who underwent gastrectomy with inadequate nodal assessment.

Gastrectomy Gastric Cancer Lymphadenectomy N stage Staging Surveillance, Epidemiology, and End Results

Journal

World journal of gastrointestinal surgery
ISSN: 1948-9366
Titre abrégé: World J Gastrointest Surg
Pays: United States
ID NLM: 101532473

Informations de publication

Date de publication:
27 Nov 2021
Historique:
received: 28 04 2021
revised: 30 06 2021
accepted: 22 10 2021
entrez: 24 12 2021
pubmed: 25 12 2021
medline: 25 12 2021
Statut: ppublish

Résumé

Gastric cancer is an aggressive disease with frequent lymph node (LN) involvement. The NCCN recommends a D2 lymphadenectomy and the harvesting of at least 16 LNs. This threshold has been the subject of great debate, not only for the extent of surgery but also for more appropriate staging. The reclassification of stage IIB through IIIC based on N3b nodal staging in the eighth edition of the American Joint Committee on Cancer (AJCC) staging system highlights the efforts to more accurately discriminate survival expectancy based on nodal number. Furthermore, studies have suggested that pathologic assessment of 30 or more LNs improve prognostic accuracy and is required for proper staging of gastric cancer. To evaluate the long-term survival of advanced gastric cancer patients who deviated from expected survival curves because of inadequate nodal evaluation. Eligible patients were identified from the Surveillance, Epidemiology, and End Results database. Those with stage II-III gastric cancer were considered for inclusion. Three groups were compared based on the number of analyzed LNs. They were inadequate LN assessment (ILA, < 16 LNs), adequate LN assessment (ALA, 16-29 LNs), and optimal LN assessment (OLA, ≥ 30 LNs). The main outcomes were overall survival (OS) and cancer-specific survival. Data were analyzed by the Kaplan-Meier product-limit method, log-rank test, hazard risk, and Cox proportional univariate and multivariate models. Propensity score matching (PSM) was used to compare the ALA and OLA groups. The analysis included 11607 patients. Most had advanced T stages (T3 = 48%; T4 = 42%). The pathological AJCC stage distribution was IIA = 22%, IIB = 18%, IIIA = 26%, IIIB = 22%, and IIIC = 12%. The overall sample divided by the study objective included ILA (50%), ALA (35%), and OLA (15%). Median OS was 24 mo for the ILA group, 29 mo for the ALA group, and 34 mo for the OLA group ( Proper nodal staging is a critical issue in gastric cancer. Assessment of an inadequate number of LNs places patients at high risk of adverse long-term survival outcomes.

Sections du résumé

BACKGROUND BACKGROUND
Gastric cancer is an aggressive disease with frequent lymph node (LN) involvement. The NCCN recommends a D2 lymphadenectomy and the harvesting of at least 16 LNs. This threshold has been the subject of great debate, not only for the extent of surgery but also for more appropriate staging. The reclassification of stage IIB through IIIC based on N3b nodal staging in the eighth edition of the American Joint Committee on Cancer (AJCC) staging system highlights the efforts to more accurately discriminate survival expectancy based on nodal number. Furthermore, studies have suggested that pathologic assessment of 30 or more LNs improve prognostic accuracy and is required for proper staging of gastric cancer.
AIM OBJECTIVE
To evaluate the long-term survival of advanced gastric cancer patients who deviated from expected survival curves because of inadequate nodal evaluation.
METHODS METHODS
Eligible patients were identified from the Surveillance, Epidemiology, and End Results database. Those with stage II-III gastric cancer were considered for inclusion. Three groups were compared based on the number of analyzed LNs. They were inadequate LN assessment (ILA, < 16 LNs), adequate LN assessment (ALA, 16-29 LNs), and optimal LN assessment (OLA, ≥ 30 LNs). The main outcomes were overall survival (OS) and cancer-specific survival. Data were analyzed by the Kaplan-Meier product-limit method, log-rank test, hazard risk, and Cox proportional univariate and multivariate models. Propensity score matching (PSM) was used to compare the ALA and OLA groups.
RESULTS RESULTS
The analysis included 11607 patients. Most had advanced T stages (T3 = 48%; T4 = 42%). The pathological AJCC stage distribution was IIA = 22%, IIB = 18%, IIIA = 26%, IIIB = 22%, and IIIC = 12%. The overall sample divided by the study objective included ILA (50%), ALA (35%), and OLA (15%). Median OS was 24 mo for the ILA group, 29 mo for the ALA group, and 34 mo for the OLA group (
CONCLUSION CONCLUSIONS
Proper nodal staging is a critical issue in gastric cancer. Assessment of an inadequate number of LNs places patients at high risk of adverse long-term survival outcomes.

Identifiants

pubmed: 34950434
doi: 10.4240/wjgs.v13.i11.1463
pmc: PMC8649557
doi:

Types de publication

Journal Article

Langues

eng

Pagination

1463-1483

Informations de copyright

©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.

Déclaration de conflit d'intérêts

Conflict-of-interest statement: The authors declare that they have no conflicting interests.

Références

Ann Surg. 2016 Jul;264(1):114-20
pubmed: 26945155
J Gastric Cancer. 2017 Sep;17(3):212-219
pubmed: 28970951
J Am Coll Surg. 2017 Apr;224(4):546-555
pubmed: 28017807
Br J Cancer. 2001 Jan 5;84(1):64-71
pubmed: 11139315
Cancer. 2006 Nov 1;107(9):2143-51
pubmed: 17001662
Gastric Cancer. 2012 Sep;15 Suppl 1:S70-88
pubmed: 22895615
Ann Surg Oncol. 2005 Dec;12(12):981-7
pubmed: 16244801
Stat Med. 2011 May 20;30(11):1292-301
pubmed: 21337595
J Egypt Natl Canc Inst. 2019 Oct 22;31(1):2
pubmed: 32372269
Ann Surg Oncol. 2010 Dec;17(12):3077-9
pubmed: 20882416
Ann Oncol. 2009 May;20(5):897-905
pubmed: 19179553

Auteurs

Jacopo Desiderio (J)

Department of Digestive Surgery, St. Mary's Hospital, Terni 05100, Italy.

Andrea Sagnotta (A)

Department of General Surgery and Surgical Oncology, San Filippo Neri Hospital, Rome 00135, Italy.

Irene Terrenato (I)

Biostatistics and Bioinformatic Unit, Scientific Direction, IRCCS Regina Elena National Cancer Institute, Rome 00144, Italy.

Eleonora Garofoli (E)

Department of Medical Oncology, St. Mary's Hospital, Terni 05100, Italy.

Claudia Mosillo (C)

Department of Medical Oncology, St. Mary's Hospital, Terni 05100, Italy.

Stefano Trastulli (S)

Department of Digestive Surgery, St. Mary's Hospital, Terni 05100, Italy.

Federica Arteritano (F)

Department of Digestive Surgery, St. Mary's Hospital, Terni 05100, Italy.

Federico Tozzi (F)

Division of Surgical Oncology and Endocrine Surgery, Mays Cancer Center, University of Texas Health Science Center San Antonio, San Antonio, TX 78229, United States.

Vito D'Andrea (V)

Department of Surgical Sciences, Sapienza University of Rome, Rome 00161, Italy.

Yuman Fong (Y)

Division of Surgical Oncology, Department of Surgery, City of Hope National Medical Center, Duarte, LA, 91010, United States.

Yanghee Woo (Y)

Division of Surgical Oncology, Department of Surgery, City of Hope National Medical Center, Duarte, LA, 91010, United States.

Sergio Bracarda (S)

Department of Medical Oncology, St. Mary's Hospital, Terni 05100, Italy.

Amilcare Parisi (A)

Department of Digestive Surgery, St. Mary's Hospital, Terni 05100, Italy.

Classifications MeSH